Last checked at 25 Jun 2021 07:00
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN (TOGETHER, THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL ("RESTRICTED JURISDICTION"). THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE SECURITIES DISCUSSED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR THE REPUBLIC OF IRELAND.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN ANGLE PLC IN ANY JURISDICTION IN WHICH ANY SUCH, OFFER OR SOLICITATION WOULD BE UNLAWFUL.
25 June 2021
ANGLE plc
("ANGLE" or the "Company")
Result of Accelerated Bookbuild
Funds will allow the Company to pursue major prostate opportunity
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that, further to the announcement made yesterday, the Company has successfully raised gross proceeds of £20.0 million by conditionally placing 17,241,380 Placing Shares at a price of 116 pence per New Ordinary Share with new and existing investors.
The Issue Price represents a discount of approximately 6.83 per cent. to the closing mid-market price of an Ordinary Share of 124.50 pence on 23 June 2021. The Placing Shares represent approximately 7.40 per cent. of the Company's Enlarged Issued Share Capital.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"We would like to thank our shareholders for their continued strong support and welcome new shareholders to the ANGLE register. The proceeds from this Placing will enable ANGLE to add to the current momentum in the commercialisation process of our Parsortix system and open up new market opportunities in Prostate Cancer diagnosis, an area of significant medical need. ANGLE looks forward to announcing further progress on multiple fronts in H2 CY21, including the prospect of FDA clearance for the Parsortix platform."
Use of Proceeds:
Prostate cancer opportunity | £7m |
Building senior management team in the United States | £3m |
Assay development capability | £2m |
Ongoing operations for breast and ovarian cancers and strengthen balance sheet for pharma services | £8m |
Total | £20m |
Admission
The Placing is conditional, inter alia, upon the Admission becoming effective. Application has been made to the London Stock Exchange for the 17,241,380 New Ordinary Shares to be admitted to trading on AIM ("Admission") and, subject to the Placing Agreement not having been terminated in accordance with its terms, it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 1 July 2021.
On Admission, the total number of Ordinary Shares in issue will be 233,109,225 and the total number of voting rights will therefore be 233,109,225. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released yesterday under RNS number 0748D unless the context requires otherwise.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations
| |
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley ECM - Alice Lane, Sunila de Silva | +44 (0)20 7220 0500 |
WG Partners (Joint Broker) Claes Spång, Nigel Barnes, Nigel Birks | +44 (0) 203 705 9330
|
Beech Hill Securities (US Broker) George Billington | +1 646 352 1368
|
FTI Consulting Simon Conway, Ciara Martin, Stephanie Cuthbert Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR. In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. Due to the publication of this Announcement, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.